Skip to main content

Market Overview

Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder

Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder
  • Karyopharm Therapeutics Inc (NASDAQ: KPTIannounced updated data from Phase 1/2 trial of eltanexor (ATG-016) for patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS).
  • Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
  • Of the 15 patients evaluable for efficacy, 7 (47%) had marrow complete response (mCR), and 5 (33%) had stable disease (SD) for a total disease control rate of 80%.
  • In the 10 mg cohort (n=5), all patients derived clinical benefit with three patients (60%) reaching mCR and two patients (40%) reaching SD.
  • In the 20 mg cohort (n=10), 4 patients (40%) had mCR and 3 (30%) had SD.
  • Four patients had hematologic improvement (HI) and became transfusion-independent for at least eight weeks, including two patients with tri-lineage HI.
  • The overall survival (OS) for patients who reached mCR (n=7) was 11.86 months, compared to 8.67 months for patients who did not reach mCR (n=8).
  • Patients with the disease control (n=12) had numerically longer median overall survival (mOS) of 9.86 months vs. 3.15 months for patients with progressive disease.
  • Patients with HI had an mOS of 10.58 months.
  • Price Action: KPTI shares are up 6.42% at $10.04 during the market session on the last check Wednesday.

Related Articles (KPTI)

View Comments and Join the Discussion!

Posted-In: Blood Disorders Briefs myelodysplastic syndromeBiotech News Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at